(Q44036716)

29 November 2017

title

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine (English)

1 reference

Woodchuck hepatitis virus

29 November 2017

main subject

object named as

woodchuck hepatitis virus

1 reference

7

Raymond F Schinazi

1 reference

29 November 2017

5

John L Gerin

1 reference

29 November 2017

6

Bud C Tennant

1 reference

29 November 2017

2

Brent E Korba

1 reference

29 November 2017

Kathleen M Tatti

1

1 reference

29 November 2017

Heather L Stang

series ordinal

3

1 reference

29 November 2017

Simon Peek

series ordinal

4

1 reference

29 November 2017

publication date

1 July 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

55

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

141-150

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Hepatocellular Carcinoma and Hepatitis B Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Sequence comparison of woodchuck hepatitis virus replicative forms shows conservation of the genome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

The molecular biology of the hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Complete nucleotide sequence of a molecular clone of woodchuck hepatitis virus that is infectious in the natural host

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Cell-based and animal models for hepatitis B and C viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900019-0

7 January 2021

10.1016/S0166-3542(02)00019-0

Identifiers

DOI

1 reference

29 November 2017

1 reference